Literature DB >> 23961576

Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting.

K J Farley1, Kerryn L Barned, Tim M Crozier.   

Abstract

OBJECTIVE: To determine how frequently stress ulcer prophylaxis (SUP) medications prescribed in the intensive care unit are inappropriately continued on the ward and on hospital discharge.
DESIGN: Retrospective cohort study; chart review.
SETTING: Two Australian ICUs: one tertiary centre and one metropolitan centre. PARTICIPANTS: We included 387 adult, non-pregnant patients who were admitted to the ICU between 1 February 2011 and 31 March 2011 and who survived to hospital discharge. MAIN OUTCOME MEASURES: Rate of unnecessary continuation of ICU-prescribed SUP medications on the ward and on discharge from hospital.
RESULTS: While in the ICU, 329 of the 387 patients (85%) were prescribed SUP medications. Of the 233 patients who had not been taking acid-suppressive medications before admission to the ICU, 190 were prescribed SUP medications in the ICU. Of these 190 patients, most (63%) had their SUP continued in the ward without any obvious indication, and many (39%) had their SUP medications inappropriately continued on discharge from hospital.
CONCLUSIONS: SUP medications commenced in ICU are frequently continued unnecessarily, both in the wards and hospital discharge.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23961576

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  9 in total

Review 1.  Stress ulceration: prevalence, pathology and association with adverse outcomes.

Authors:  Mark P Plummer; Annika Reintam Blaser; Adam M Deane
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

Review 2.  What's new with stress ulcer prophylaxis in the ICU?

Authors:  Søren Marker; Mette Krag; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2017-02-25       Impact factor: 17.440

3.  The SUP-ICU Trial: Does It Confirm or Condemn the Practice of Stress Ulcer Prophylaxis?

Authors:  Jeffrey F Barletta; Mitchell S Buckley; Robert MacLaren
Journal:  Hosp Pharm       Date:  2019-08-02

4.  Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?

Authors:  Chang Soo Eun
Journal:  Gut Liver       Date:  2017-11-15       Impact factor: 4.519

5.  A Successful Pharmacist-Based Quality Initiative to Reduce Inappropriate Stress Ulcer Prophylaxis Use in an Academic Medical Intensive Care Unit.

Authors:  Umair Masood; Anuj Sharma; Zabeer Bhatti; Jessica Carroll; Amit Bhardwaj; Devamohan Sivalingam; Amit S Dhamoon
Journal:  Inquiry       Date:  2018 Jan-Dec       Impact factor: 1.730

6.  Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit.

Authors:  João João Mendes; Mário Jorge Silva; Luís Silva Miguel; Maria Albertina Gonçalves; Maria João Oliveira; Catarina da Luz Oliveira; João Gouveia
Journal:  Rev Bras Ter Intensiva       Date:  2019-02-28

7.  Adherence to a stress ulcer prophylaxis protocol by critically ill patients: a prospective cohort study.

Authors:  Yuri de Albuquerque Pessoa Dos Santos; Mauricio Staib Younes-Ibrahim; Lucas Lonardoni Crozatti; Dante Raglione; Luis Carlos Maia Cardozo Junior; Bruno Adler Maccagnan Pinheiro Besen; Leandro Utino Taniguchi; Marcelo Park; Pedro Vitale Mendes
Journal:  Rev Bras Ter Intensiva       Date:  2020-05-08

8.  Potentially inappropriate medications at discharge among elderly patients at a single tertiary emergency medical institution in Japan: a retrospective cross-sectional observational study.

Authors:  Kenta Aida; Kazunari Azuma; Shiro Mishima; Yuri Ishii; Shoji Suzuki; Jun Oda
Journal:  Acute Med Surg       Date:  2021-11-29

Review 9.  Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis.

Authors:  Hui-Bin Huang; Wei Jiang; Chun-Yao Wang; Han-Yu Qin; Bin Du
Journal:  Crit Care       Date:  2018-01-28       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.